Incyte Corporation (NASDAQ: INCY) Stock Competitors & Peer Comparison
See INCY's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for INCY and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| INCY | $119.52 | -2.82% | 24.2B | 16.06 | $7.44 | N/A |
| VRTX | $477.10 | -0.95% | 121.1B | 25.35 | $18.82 | N/A |
| REGN | $762.63 | +3.29% | 78.6B | 16.71 | $45.63 | +0.48% |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ARGX | $853.82 | -3.26% | 54.3B | 78.75 | $11.08 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| RVMDW | $9.57 | -3.14% | 42.7B | -2.32 | -$4.15 | N/A |
| RVMD | $187.53 | -2.41% | 39.9B | -26.52 | -$7.07 | N/A |
| ONC | $316.01 | -1.88% | 33.8B | 70.70 | $4.47 | N/A |
| ALNY | $205.52 | -28.30% | 27.4B | 37.02 | $5.55 | N/A |
Stock Comparison
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)
INCY vs VRTX Comparison August 2026
Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCY stands at 24.2B. In comparison, VRTX has a market cap of 121.1B. Regarding current trading prices, INCY is priced at $119.52 on the NASDAQ, while VRTX trades at $477.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCY currently has a P/E ratio of 16.06, whereas VRTX's P/E ratio is 25.35. In terms of profitability, INCY's ROE is +0.30%, compared to VRTX's ROE of +0.24%. Regarding short-term risk, INCY is more volatile compared to VRTX. This indicates higher risk in terms of short-term price fluctuations for INCY.Check VRTX's competition here
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)
INCY vs REGN Comparison August 2026
Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCY stands at 24.2B. In comparison, REGN has a market cap of 78.6B. Regarding current trading prices, INCY is priced at $119.52 on the NASDAQ, while REGN trades at $762.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCY currently has a P/E ratio of 16.06, whereas REGN's P/E ratio is 16.71. In terms of profitability, INCY's ROE is +0.30%, compared to REGN's ROE of +0.18%. Regarding short-term risk, INCY is less volatile compared to REGN. This indicates lower risk in terms of short-term price fluctuations for INCY.Check REGN's competition here
Verona Pharma plc (NASDAQ: VRNA)
INCY vs VRNA Comparison August 2026
Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCY stands at 24.2B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, INCY is priced at $119.52 on the NASDAQ, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCY currently has a P/E ratio of 16.06, whereas VRNA's P/E ratio is -102.80. In terms of profitability, INCY's ROE is +0.30%, compared to VRNA's ROE of -0.02%. Regarding short-term risk, INCY is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for INCY.Check VRNA's competition here
argenx SE (NASDAQ: ARGX)
INCY vs ARGX Comparison August 2026
Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCY stands at 24.2B. In comparison, ARGX has a market cap of 54.3B. Regarding current trading prices, INCY is priced at $119.52 on the NASDAQ, while ARGX trades at $853.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCY currently has a P/E ratio of 16.06, whereas ARGX's P/E ratio is 78.75. In terms of profitability, INCY's ROE is +0.30%, compared to ARGX's ROE of +0.32%. Regarding short-term risk, INCY is more volatile compared to ARGX. This indicates higher risk in terms of short-term price fluctuations for INCY.Check ARGX's competition here
Seagen Inc. (NASDAQ: SGEN)
INCY vs SGEN Comparison August 2026
Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCY stands at 24.2B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, INCY is priced at $119.52 on the NASDAQ, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCY currently has a P/E ratio of 16.06, whereas SGEN's P/E ratio is -57.19. In terms of profitability, INCY's ROE is +0.30%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, INCY is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for INCY.Check SGEN's competition here
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW)
INCY vs RVMDW Comparison August 2026
Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCY stands at 24.2B. In comparison, RVMDW has a market cap of 42.7B. Regarding current trading prices, INCY is priced at $119.52 on the NASDAQ, while RVMDW trades at $9.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCY currently has a P/E ratio of 16.06, whereas RVMDW's P/E ratio is -2.32. In terms of profitability, INCY's ROE is +0.30%, compared to RVMDW's ROE of -0.83%. Regarding short-term risk, INCY is more volatile compared to RVMDW. This indicates higher risk in terms of short-term price fluctuations for INCY.Check RVMDW's competition here
Revolution Medicines, Inc. (NASDAQ: RVMD)
INCY vs RVMD Comparison August 2026
Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCY stands at 24.2B. In comparison, RVMD has a market cap of 39.9B. Regarding current trading prices, INCY is priced at $119.52 on the NASDAQ, while RVMD trades at $187.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCY currently has a P/E ratio of 16.06, whereas RVMD's P/E ratio is -26.52. In terms of profitability, INCY's ROE is +0.30%, compared to RVMD's ROE of -0.83%. Regarding short-term risk, INCY is more volatile compared to RVMD. This indicates higher risk in terms of short-term price fluctuations for INCY.Check RVMD's competition here
BeOne Medicines AG (NASDAQ: ONC)
INCY vs ONC Comparison August 2026
Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCY stands at 24.2B. In comparison, ONC has a market cap of 33.8B. Regarding current trading prices, INCY is priced at $119.52 on the NASDAQ, while ONC trades at $316.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCY currently has a P/E ratio of 16.06, whereas ONC's P/E ratio is 70.70. In terms of profitability, INCY's ROE is +0.30%, compared to ONC's ROE of +0.12%. Regarding short-term risk, INCY is more volatile compared to ONC. This indicates higher risk in terms of short-term price fluctuations for INCY.Check ONC's competition here
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)
INCY vs ALNY Comparison August 2026
Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCY stands at 24.2B. In comparison, ALNY has a market cap of 27.4B. Regarding current trading prices, INCY is priced at $119.52 on the NASDAQ, while ALNY trades at $205.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCY currently has a P/E ratio of 16.06, whereas ALNY's P/E ratio is 37.02. In terms of profitability, INCY's ROE is +0.30%, compared to ALNY's ROE of +0.94%. Regarding short-term risk, INCY is less volatile compared to ALNY. This indicates lower risk in terms of short-term price fluctuations for INCY.Check ALNY's competition here
Roivant Sciences Ltd. (NASDAQ: ROIV)
INCY vs ROIV Comparison August 2026
Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCY stands at 24.2B. In comparison, ROIV has a market cap of 24.5B. Regarding current trading prices, INCY is priced at $119.52 on the NASDAQ, while ROIV trades at $33.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCY currently has a P/E ratio of 16.06, whereas ROIV's P/E ratio is -34.86. In terms of profitability, INCY's ROE is +0.30%, compared to ROIV's ROE of -0.07%. Regarding short-term risk, INCY is more volatile compared to ROIV. This indicates higher risk in terms of short-term price fluctuations for INCY.Check ROIV's competition here
BioNTech SE (NASDAQ: BNTX)
INCY vs BNTX Comparison August 2026
Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCY stands at 24.2B. In comparison, BNTX has a market cap of 22.9B. Regarding current trading prices, INCY is priced at $119.52 on the NASDAQ, while BNTX trades at $90.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCY currently has a P/E ratio of 16.06, whereas BNTX's P/E ratio is -19.61. In terms of profitability, INCY's ROE is +0.30%, compared to BNTX's ROE of -0.07%. Regarding short-term risk, INCY is more volatile compared to BNTX. This indicates higher risk in terms of short-term price fluctuations for INCY.Check BNTX's competition here
United Therapeutics Corporation (NASDAQ: UTHR)
INCY vs UTHR Comparison August 2026
Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCY stands at 24.2B. In comparison, UTHR has a market cap of 22B. Regarding current trading prices, INCY is priced at $119.52 on the NASDAQ, while UTHR trades at $517.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCY currently has a P/E ratio of 16.06, whereas UTHR's P/E ratio is 19.10. In terms of profitability, INCY's ROE is +0.30%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, INCY is more volatile compared to UTHR. This indicates higher risk in terms of short-term price fluctuations for INCY.Check UTHR's competition here
Moderna, Inc. (NASDAQ: MRNA)
INCY vs MRNA Comparison August 2026
Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCY stands at 24.2B. In comparison, MRNA has a market cap of 21.8B. Regarding current trading prices, INCY is priced at $119.52 on the NASDAQ, while MRNA trades at $54.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCY currently has a P/E ratio of 16.06, whereas MRNA's P/E ratio is -6.73. In terms of profitability, INCY's ROE is +0.30%, compared to MRNA's ROE of -0.39%. Regarding short-term risk, INCY is less volatile compared to MRNA. This indicates lower risk in terms of short-term price fluctuations for INCY.Check MRNA's competition here
Insmed Incorporated (NASDAQ: INSM)
INCY vs INSM Comparison August 2026
Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCY stands at 24.2B. In comparison, INSM has a market cap of 21.4B. Regarding current trading prices, INCY is priced at $119.52 on the NASDAQ, while INSM trades at $98.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCY currently has a P/E ratio of 16.06, whereas INSM's P/E ratio is -17.15. In terms of profitability, INCY's ROE is +0.30%, compared to INSM's ROE of -1.30%. Regarding short-term risk, INCY is less volatile compared to INSM. This indicates lower risk in terms of short-term price fluctuations for INCY.Check INSM's competition here
BeiGene, Ltd. (NASDAQ: BGNE)
INCY vs BGNE Comparison August 2026
Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCY stands at 24.2B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, INCY is priced at $119.52 on the NASDAQ, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCY currently has a P/E ratio of 16.06, whereas BGNE's P/E ratio is -22.55. In terms of profitability, INCY's ROE is +0.30%, compared to BGNE's ROE of +0.12%. Regarding short-term risk, INCY is more volatile compared to BGNE. This indicates higher risk in terms of short-term price fluctuations for INCY.Check BGNE's competition here
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT)
INCY vs DNA-WT Comparison August 2026
Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCY stands at 24.2B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, INCY is priced at $119.52 on the NASDAQ, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCY currently has a P/E ratio of 16.06, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, INCY's ROE is +0.30%, compared to DNA-WT's ROE of -0.57%. Regarding short-term risk, INCY is less volatile compared to DNA-WT. This indicates lower risk in terms of short-term price fluctuations for INCY.Check DNA-WT's competition here
Genmab A/S (NASDAQ: GMAB)
INCY vs GMAB Comparison August 2026
Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCY stands at 24.2B. In comparison, GMAB has a market cap of 17.7B. Regarding current trading prices, INCY is priced at $119.52 on the NASDAQ, while GMAB trades at $28.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCY currently has a P/E ratio of 16.06, whereas GMAB's P/E ratio is 20.77. In terms of profitability, INCY's ROE is +0.30%, compared to GMAB's ROE of +0.15%. Regarding short-term risk, INCY is more volatile compared to GMAB. This indicates higher risk in terms of short-term price fluctuations for INCY.Check GMAB's competition here
Neurocrine Biosciences, Inc. (NASDAQ: NBIX)
INCY vs NBIX Comparison August 2026
Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCY stands at 24.2B. In comparison, NBIX has a market cap of 16.8B. Regarding current trading prices, INCY is priced at $119.52 on the NASDAQ, while NBIX trades at $166.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCY currently has a P/E ratio of 16.06, whereas NBIX's P/E ratio is 24.10. In terms of profitability, INCY's ROE is +0.30%, compared to NBIX's ROE of +0.21%. Regarding short-term risk, INCY is less volatile compared to NBIX. This indicates lower risk in terms of short-term price fluctuations for INCY.Check NBIX's competition here
Jazz Pharmaceuticals plc (NASDAQ: JAZZ)
INCY vs JAZZ Comparison August 2026
Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCY stands at 24.2B. In comparison, JAZZ has a market cap of 15.9B. Regarding current trading prices, INCY is priced at $119.52 on the NASDAQ, while JAZZ trades at $252.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCY currently has a P/E ratio of 16.06, whereas JAZZ's P/E ratio is 19.66. In terms of profitability, INCY's ROE is +0.30%, compared to JAZZ's ROE of +0.01%. Regarding short-term risk, INCY is more volatile compared to JAZZ. This indicates higher risk in terms of short-term price fluctuations for INCY.Check JAZZ's competition here
BridgeBio Pharma, Inc. (NASDAQ: BBIO)
INCY vs BBIO Comparison August 2026
Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCY stands at 24.2B. In comparison, BBIO has a market cap of 15.7B. Regarding current trading prices, INCY is priced at $119.52 on the NASDAQ, while BBIO trades at $80.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCY currently has a P/E ratio of 16.06, whereas BBIO's P/E ratio is -21.41. In terms of profitability, INCY's ROE is +0.30%, compared to BBIO's ROE of +0.36%. Regarding short-term risk, INCY is less volatile compared to BBIO. This indicates lower risk in terms of short-term price fluctuations for INCY.Check BBIO's competition here
Ascendis Pharma A/S (NASDAQ: ASND)
INCY vs ASND Comparison August 2026
Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCY stands at 24.2B. In comparison, ASND has a market cap of 15.1B. Regarding current trading prices, INCY is priced at $119.52 on the NASDAQ, while ASND trades at $243.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCY currently has a P/E ratio of 16.06, whereas ASND's P/E ratio is -100.79. In terms of profitability, INCY's ROE is +0.30%, compared to ASND's ROE of -56.42%. Regarding short-term risk, INCY is less volatile compared to ASND. This indicates lower risk in terms of short-term price fluctuations for INCY.Check ASND's competition here
Exelixis, Inc. (NASDAQ: EXEL)
INCY vs EXEL Comparison August 2026
Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCY stands at 24.2B. In comparison, EXEL has a market cap of 13.3B. Regarding current trading prices, INCY is priced at $119.52 on the NASDAQ, while EXEL trades at $53.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCY currently has a P/E ratio of 16.06, whereas EXEL's P/E ratio is 15.88. In terms of profitability, INCY's ROE is +0.30%, compared to EXEL's ROE of +0.40%. Regarding short-term risk, INCY is less volatile compared to EXEL. This indicates lower risk in terms of short-term price fluctuations for INCY.Check EXEL's competition here
Karuna Therapeutics, Inc. (NASDAQ: KRTX)
INCY vs KRTX Comparison August 2026
Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCY stands at 24.2B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, INCY is priced at $119.52 on the NASDAQ, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCY currently has a P/E ratio of 16.06, whereas KRTX's P/E ratio is -28.09. In terms of profitability, INCY's ROE is +0.30%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, INCY is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for INCY.Check KRTX's competition here
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR)
INCY vs ARWR Comparison August 2026
Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCY stands at 24.2B. In comparison, ARWR has a market cap of 11.9B. Regarding current trading prices, INCY is priced at $119.52 on the NASDAQ, while ARWR trades at $84.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCY currently has a P/E ratio of 16.06, whereas ARWR's P/E ratio is -39.37. In terms of profitability, INCY's ROE is +0.30%, compared to ARWR's ROE of -0.55%. Regarding short-term risk, INCY is more volatile compared to ARWR. This indicates higher risk in terms of short-term price fluctuations for INCY.Check ARWR's competition here
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)
INCY vs BMRN Comparison August 2026
Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCY stands at 24.2B. In comparison, BMRN has a market cap of 11.6B. Regarding current trading prices, INCY is priced at $119.52 on the NASDAQ, while BMRN trades at $60.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCY currently has a P/E ratio of 16.06, whereas BMRN's P/E ratio is 28.86. In terms of profitability, INCY's ROE is +0.30%, compared to BMRN's ROE of +0.04%. Regarding short-term risk, INCY is more volatile compared to BMRN. This indicates higher risk in terms of short-term price fluctuations for INCY.Check BMRN's competition here
Bio-Techne Corporation (NASDAQ: TECH)
INCY vs TECH Comparison August 2026
Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCY stands at 24.2B. In comparison, TECH has a market cap of 11.3B. Regarding current trading prices, INCY is priced at $119.52 on the NASDAQ, while TECH trades at $72.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCY currently has a P/E ratio of 16.06, whereas TECH's P/E ratio is 37.16. In terms of profitability, INCY's ROE is +0.30%, compared to TECH's ROE of +0.05%. Regarding short-term risk, INCY is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for INCY.Check TECH's competition here
Avidity Biosciences Inc (NASDAQ: RNAM)
INCY vs RNAM Comparison August 2026
Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCY stands at 24.2B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, INCY is priced at $119.52 on the NASDAQ, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCY currently has a P/E ratio of 16.06, whereas RNAM's P/E ratio is -17.39. In terms of profitability, INCY's ROE is +0.30%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, INCY is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for INCY.Check RNAM's competition here
Axsome Therapeutics, Inc. (NASDAQ: AXSM)
INCY vs AXSM Comparison August 2026
Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCY stands at 24.2B. In comparison, AXSM has a market cap of 11.2B. Regarding current trading prices, INCY is priced at $119.52 on the NASDAQ, while AXSM trades at $217.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCY currently has a P/E ratio of 16.06, whereas AXSM's P/E ratio is -56.92. In terms of profitability, INCY's ROE is +0.30%, compared to AXSM's ROE of -2.60%. Regarding short-term risk, INCY is less volatile compared to AXSM. This indicates lower risk in terms of short-term price fluctuations for INCY.Check AXSM's competition here
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)
INCY vs MDGL Comparison August 2026
Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCY stands at 24.2B. In comparison, MDGL has a market cap of 10.8B. Regarding current trading prices, INCY is priced at $119.52 on the NASDAQ, while MDGL trades at $467.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCY currently has a P/E ratio of 16.06, whereas MDGL's P/E ratio is -36.51. In terms of profitability, INCY's ROE is +0.30%, compared to MDGL's ROE of -0.57%. Regarding short-term risk, INCY is less volatile compared to MDGL. This indicates lower risk in terms of short-term price fluctuations for INCY.Check MDGL's competition here
Summit Therapeutics Inc. (NASDAQ: SMMT)
INCY vs SMMT Comparison August 2026
Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCY stands at 24.2B. In comparison, SMMT has a market cap of 10.1B. Regarding current trading prices, INCY is priced at $119.52 on the NASDAQ, while SMMT trades at $13.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCY currently has a P/E ratio of 16.06, whereas SMMT's P/E ratio is -8.14. In terms of profitability, INCY's ROE is +0.30%, compared to SMMT's ROE of -2.04%. Regarding short-term risk, INCY is less volatile compared to SMMT. This indicates lower risk in terms of short-term price fluctuations for INCY.Check SMMT's competition here
Krystal Biotech, Inc. (NASDAQ: KRYS)
INCY vs KRYS Comparison August 2026
Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCY stands at 24.2B. In comparison, KRYS has a market cap of 10.1B. Regarding current trading prices, INCY is priced at $119.52 on the NASDAQ, while KRYS trades at $341.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCY currently has a P/E ratio of 16.06, whereas KRYS's P/E ratio is 45.60. In terms of profitability, INCY's ROE is +0.30%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, INCY is less volatile compared to KRYS. This indicates lower risk in terms of short-term price fluctuations for INCY.Check KRYS's competition here
Halozyme Therapeutics, Inc. (NASDAQ: HALO)
INCY vs HALO Comparison August 2026
Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCY stands at 24.2B. In comparison, HALO has a market cap of 9.8B. Regarding current trading prices, INCY is priced at $119.52 on the NASDAQ, while HALO trades at $82.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCY currently has a P/E ratio of 16.06, whereas HALO's P/E ratio is 17.87. In terms of profitability, INCY's ROE is +0.30%, compared to HALO's ROE of +1.26%. Regarding short-term risk, INCY is more volatile compared to HALO. This indicates higher risk in terms of short-term price fluctuations for INCY.Check HALO's competition here
Cytokinetics, Incorporated (NASDAQ: CYTK)
INCY vs CYTK Comparison August 2026
Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCY stands at 24.2B. In comparison, CYTK has a market cap of 9.6B. Regarding current trading prices, INCY is priced at $119.52 on the NASDAQ, while CYTK trades at $77.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCY currently has a P/E ratio of 16.06, whereas CYTK's P/E ratio is -13.23. In terms of profitability, INCY's ROE is +0.30%, compared to CYTK's ROE of +1.40%. Regarding short-term risk, INCY is less volatile compared to CYTK. This indicates lower risk in terms of short-term price fluctuations for INCY.Check CYTK's competition here
Prometheus Biosciences, Inc. (NASDAQ: RXDX)
INCY vs RXDX Comparison August 2026
Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCY stands at 24.2B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, INCY is priced at $119.52 on the NASDAQ, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCY currently has a P/E ratio of 16.06, whereas RXDX's P/E ratio is -56.47. In terms of profitability, INCY's ROE is +0.30%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, INCY is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for INCY.Check RXDX's competition here
Abivax S.A. (NASDAQ: ABVX)
INCY vs ABVX Comparison August 2026
Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCY stands at 24.2B. In comparison, ABVX has a market cap of 9.2B. Regarding current trading prices, INCY is priced at $119.52 on the NASDAQ, while ABVX trades at $124.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCY currently has a P/E ratio of 16.06, whereas ABVX's P/E ratio is -65.48. In terms of profitability, INCY's ROE is +0.30%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, INCY is less volatile compared to ABVX. This indicates lower risk in terms of short-term price fluctuations for INCY.Check ABVX's competition here
Nuvalent, Inc. (NASDAQ: NUVL)
INCY vs NUVL Comparison August 2026
Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCY stands at 24.2B. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, INCY is priced at $119.52 on the NASDAQ, while NUVL trades at $123.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCY currently has a P/E ratio of 16.06, whereas NUVL's P/E ratio is -21.79. In terms of profitability, INCY's ROE is +0.30%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, INCY is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for INCY.Check NUVL's competition here
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX)
INCY vs CRNX Comparison August 2026
Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCY stands at 24.2B. In comparison, CRNX has a market cap of 8.8B. Regarding current trading prices, INCY is priced at $119.52 on the NASDAQ, while CRNX trades at $83.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCY currently has a P/E ratio of 16.06, whereas CRNX's P/E ratio is -16.28. In terms of profitability, INCY's ROE is +0.30%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, INCY is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for INCY.Check CRNX's competition here
Protagonist Therapeutics, Inc. (NASDAQ: PTGX)
INCY vs PTGX Comparison August 2026
Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCY stands at 24.2B. In comparison, PTGX has a market cap of 8.8B. Regarding current trading prices, INCY is priced at $119.52 on the NASDAQ, while PTGX trades at $136.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCY currently has a P/E ratio of 16.06, whereas PTGX's P/E ratio is -75.49. In terms of profitability, INCY's ROE is +0.30%, compared to PTGX's ROE of -0.18%. Regarding short-term risk, INCY is less volatile compared to PTGX. This indicates lower risk in terms of short-term price fluctuations for INCY.Check PTGX's competition here
ImmunoGen, Inc. (NASDAQ: IMGN)
INCY vs IMGN Comparison August 2026
Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCY stands at 24.2B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, INCY is priced at $119.52 on the NASDAQ, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCY currently has a P/E ratio of 16.06, whereas IMGN's P/E ratio is -111.55. In terms of profitability, INCY's ROE is +0.30%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, INCY is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for INCY.Check IMGN's competition here
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)
INCY vs IONS Comparison August 2026
Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCY stands at 24.2B. In comparison, IONS has a market cap of 8.6B. Regarding current trading prices, INCY is priced at $119.52 on the NASDAQ, while IONS trades at $51.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCY currently has a P/E ratio of 16.06, whereas IONS's P/E ratio is -30.10. In terms of profitability, INCY's ROE is +0.30%, compared to IONS's ROE of -1.11%. Regarding short-term risk, INCY is less volatile compared to IONS. This indicates lower risk in terms of short-term price fluctuations for INCY.Check IONS's competition here
Praxis Precision Medicines, Inc. (NASDAQ: PRAX)
INCY vs PRAX Comparison August 2026
Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCY stands at 24.2B. In comparison, PRAX has a market cap of 8.6B. Regarding current trading prices, INCY is priced at $119.52 on the NASDAQ, while PRAX trades at $307.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCY currently has a P/E ratio of 16.06, whereas PRAX's P/E ratio is -23.02. In terms of profitability, INCY's ROE is +0.30%, compared to PRAX's ROE of -0.43%. Regarding short-term risk, INCY is less volatile compared to PRAX. This indicates lower risk in terms of short-term price fluctuations for INCY.Check PRAX's competition here
Spyre Therapeutics, Inc. (NASDAQ: SYRE)
INCY vs SYRE Comparison August 2026
Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCY stands at 24.2B. In comparison, SYRE has a market cap of 8.5B. Regarding current trading prices, INCY is priced at $119.52 on the NASDAQ, while SYRE trades at $98.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCY currently has a P/E ratio of 16.06, whereas SYRE's P/E ratio is -47.27. In terms of profitability, INCY's ROE is +0.30%, compared to SYRE's ROE of -0.31%. Regarding short-term risk, INCY is less volatile compared to SYRE. This indicates lower risk in terms of short-term price fluctuations for INCY.Check SYRE's competition here
Kymera Therapeutics, Inc. (NASDAQ: KYMR)
INCY vs KYMR Comparison August 2026
Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCY stands at 24.2B. In comparison, KYMR has a market cap of 8.5B. Regarding current trading prices, INCY is priced at $119.52 on the NASDAQ, while KYMR trades at $103.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCY currently has a P/E ratio of 16.06, whereas KYMR's P/E ratio is -29.29. In terms of profitability, INCY's ROE is +0.30%, compared to KYMR's ROE of -0.25%. Regarding short-term risk, INCY is less volatile compared to KYMR. This indicates lower risk in terms of short-term price fluctuations for INCY.Check KYMR's competition here
Alkermes plc (NASDAQ: ALKS)
INCY vs ALKS Comparison August 2026
Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCY stands at 24.2B. In comparison, ALKS has a market cap of 8.4B. Regarding current trading prices, INCY is priced at $119.52 on the NASDAQ, while ALKS trades at $48.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCY currently has a P/E ratio of 16.06, whereas ALKS's P/E ratio is 52.66. In terms of profitability, INCY's ROE is +0.30%, compared to ALKS's ROE of +0.04%. Regarding short-term risk, INCY is more volatile compared to ALKS. This indicates higher risk in terms of short-term price fluctuations for INCY.Check ALKS's competition here
Blueprint Medicines Corporation (NASDAQ: BPMC)
INCY vs BPMC Comparison August 2026
Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCY stands at 24.2B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, INCY is priced at $119.52 on the NASDAQ, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCY currently has a P/E ratio of 16.06, whereas BPMC's P/E ratio is -51.58. In terms of profitability, INCY's ROE is +0.30%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, INCY is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for INCY.Check BPMC's competition here
Apogee Therapeutics, Inc. (NASDAQ: APGE)
INCY vs APGE Comparison August 2026
Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCY stands at 24.2B. In comparison, APGE has a market cap of 8.3B. Regarding current trading prices, INCY is priced at $119.52 on the NASDAQ, while APGE trades at $134.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCY currently has a P/E ratio of 16.06, whereas APGE's P/E ratio is -30.97. In terms of profitability, INCY's ROE is +0.30%, compared to APGE's ROE of -0.33%. Regarding short-term risk, INCY is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for INCY.Check APGE's competition here
Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE)
INCY vs CERE Comparison August 2026
Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCY stands at 24.2B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, INCY is priced at $119.52 on the NASDAQ, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCY currently has a P/E ratio of 16.06, whereas CERE's P/E ratio is -16.47. In terms of profitability, INCY's ROE is +0.30%, compared to CERE's ROE of -0.72%. Regarding short-term risk, INCY is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for INCY.Check CERE's competition here
TG Therapeutics, Inc. (NASDAQ: TGTX)
INCY vs TGTX Comparison August 2026
Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCY stands at 24.2B. In comparison, TGTX has a market cap of 8B. Regarding current trading prices, INCY is priced at $119.52 on the NASDAQ, while TGTX trades at $52.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCY currently has a P/E ratio of 16.06, whereas TGTX's P/E ratio is 17.88. In terms of profitability, INCY's ROE is +0.30%, compared to TGTX's ROE of +0.87%. Regarding short-term risk, INCY is less volatile compared to TGTX. This indicates lower risk in terms of short-term price fluctuations for INCY.Check TGTX's competition here
Immunovant, Inc. (NASDAQ: IMVT)
INCY vs IMVT Comparison August 2026
Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCY stands at 24.2B. In comparison, IMVT has a market cap of 7.9B. Regarding current trading prices, INCY is priced at $119.52 on the NASDAQ, while IMVT trades at $38.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCY currently has a P/E ratio of 16.06, whereas IMVT's P/E ratio is -14.46. In terms of profitability, INCY's ROE is +0.30%, compared to IMVT's ROE of -0.68%. Regarding short-term risk, INCY is more volatile compared to IMVT. This indicates higher risk in terms of short-term price fluctuations for INCY.Check IMVT's competition here
Vaxcyte, Inc. (NASDAQ: PCVX)
INCY vs PCVX Comparison August 2026
Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCY stands at 24.2B. In comparison, PCVX has a market cap of 7.8B. Regarding current trading prices, INCY is priced at $119.52 on the NASDAQ, while PCVX trades at $54.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCY currently has a P/E ratio of 16.06, whereas PCVX's P/E ratio is -7.86. In terms of profitability, INCY's ROE is +0.30%, compared to PCVX's ROE of -0.33%. Regarding short-term risk, INCY is less volatile compared to PCVX. This indicates lower risk in terms of short-term price fluctuations for INCY.Check PCVX's competition here
ImmunityBio, Inc. (NASDAQ: IBRX)
INCY vs IBRX Comparison August 2026
Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCY stands at 24.2B. In comparison, IBRX has a market cap of 7.5B. Regarding current trading prices, INCY is priced at $119.52 on the NASDAQ, while IBRX trades at $7.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCY currently has a P/E ratio of 16.06, whereas IBRX's P/E ratio is -8.44. In terms of profitability, INCY's ROE is +0.30%, compared to IBRX's ROE of +1.39%. Regarding short-term risk, INCY is less volatile compared to IBRX. This indicates lower risk in terms of short-term price fluctuations for INCY.Check IBRX's competition here
Metsera, Inc. (NASDAQ: MTSR)
INCY vs MTSR Comparison August 2026
Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCY stands at 24.2B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, INCY is priced at $119.52 on the NASDAQ, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCY currently has a P/E ratio of 16.06, whereas MTSR's P/E ratio is -23.58. In terms of profitability, INCY's ROE is +0.30%, compared to MTSR's ROE of -0.61%. Regarding short-term risk, INCY is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for INCY.Check MTSR's competition here
Merus N.V. (NASDAQ: MRUS)
INCY vs MRUS Comparison August 2026
Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCY stands at 24.2B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, INCY is priced at $119.52 on the NASDAQ, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCY currently has a P/E ratio of 16.06, whereas MRUS's P/E ratio is -17.05. In terms of profitability, INCY's ROE is +0.30%, compared to MRUS's ROE of -0.46%. Regarding short-term risk, INCY is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for INCY.Check MRUS's competition here
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM)
INCY vs RYTM Comparison August 2026
Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCY stands at 24.2B. In comparison, RYTM has a market cap of 6.8B. Regarding current trading prices, INCY is priced at $119.52 on the NASDAQ, while RYTM trades at $99.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCY currently has a P/E ratio of 16.06, whereas RYTM's P/E ratio is -31.71. In terms of profitability, INCY's ROE is +0.30%, compared to RYTM's ROE of -2.03%. Regarding short-term risk, INCY is less volatile compared to RYTM. This indicates lower risk in terms of short-term price fluctuations for INCY.Check RYTM's competition here
Arcellx, Inc. (NASDAQ: ACLX)
INCY vs ACLX Comparison August 2026
Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCY stands at 24.2B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, INCY is priced at $119.52 on the NASDAQ, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCY currently has a P/E ratio of 16.06, whereas ACLX's P/E ratio is -28.27. In terms of profitability, INCY's ROE is +0.30%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, INCY is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for INCY.Check ACLX's competition here
Cogent Biosciences, Inc. (NASDAQ: COGT)
INCY vs COGT Comparison August 2026
Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCY stands at 24.2B. In comparison, COGT has a market cap of 6.7B. Regarding current trading prices, INCY is priced at $119.52 on the NASDAQ, while COGT trades at $38.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCY currently has a P/E ratio of 16.06, whereas COGT's P/E ratio is -18.45. In terms of profitability, INCY's ROE is +0.30%, compared to COGT's ROE of -0.83%. Regarding short-term risk, INCY is less volatile compared to COGT. This indicates lower risk in terms of short-term price fluctuations for INCY.Check COGT's competition here
Reata Pharmaceuticals, Inc. (NASDAQ: RETA)
INCY vs RETA Comparison August 2026
Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCY stands at 24.2B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, INCY is priced at $119.52 on the NASDAQ, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCY currently has a P/E ratio of 16.06, whereas RETA's P/E ratio is -66.29. In terms of profitability, INCY's ROE is +0.30%, compared to RETA's ROE of +0.47%. Regarding short-term risk, INCY is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for INCY.Check RETA's competition here
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM)
INCY vs MIRM Comparison August 2026
Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCY stands at 24.2B. In comparison, MIRM has a market cap of 6.5B. Regarding current trading prices, INCY is priced at $119.52 on the NASDAQ, while MIRM trades at $105.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCY currently has a P/E ratio of 16.06, whereas MIRM's P/E ratio is -7.78. In terms of profitability, INCY's ROE is +0.30%, compared to MIRM's ROE of -2.89%. Regarding short-term risk, INCY is less volatile compared to MIRM. This indicates lower risk in terms of short-term price fluctuations for INCY.Check MIRM's competition here
Belite Bio, Inc (NASDAQ: BLTE)
INCY vs BLTE Comparison August 2026
Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCY stands at 24.2B. In comparison, BLTE has a market cap of 6.4B. Regarding current trading prices, INCY is priced at $119.52 on the NASDAQ, while BLTE trades at $158.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCY currently has a P/E ratio of 16.06, whereas BLTE's P/E ratio is -84.82. In terms of profitability, INCY's ROE is +0.30%, compared to BLTE's ROE of -0.18%. Regarding short-term risk, INCY is less volatile compared to BLTE. This indicates lower risk in terms of short-term price fluctuations for INCY.Check BLTE's competition here
Erasca, Inc. (NASDAQ: ERAS)
INCY vs ERAS Comparison August 2026
Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCY stands at 24.2B. In comparison, ERAS has a market cap of 6.3B. Regarding current trading prices, INCY is priced at $119.52 on the NASDAQ, while ERAS trades at $18.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCY currently has a P/E ratio of 16.06, whereas ERAS's P/E ratio is -19.51. In terms of profitability, INCY's ROE is +0.30%, compared to ERAS's ROE of -0.77%. Regarding short-term risk, INCY is less volatile compared to ERAS. This indicates lower risk in terms of short-term price fluctuations for INCY.Check ERAS's competition here
CG Oncology Inc. (NASDAQ: CGON)
INCY vs CGON Comparison August 2026
Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCY stands at 24.2B. In comparison, CGON has a market cap of 6.3B. Regarding current trading prices, INCY is priced at $119.52 on the NASDAQ, while CGON trades at $71.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCY currently has a P/E ratio of 16.06, whereas CGON's P/E ratio is -30.55. In terms of profitability, INCY's ROE is +0.30%, compared to CGON's ROE of -0.23%. Regarding short-term risk, INCY is less volatile compared to CGON. This indicates lower risk in terms of short-term price fluctuations for INCY.Check CGON's competition here
Centessa Pharmaceuticals plc (NASDAQ: CNTA)
INCY vs CNTA Comparison August 2026
Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCY stands at 24.2B. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, INCY is priced at $119.52 on the NASDAQ, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCY currently has a P/E ratio of 16.06, whereas CNTA's P/E ratio is -22.63. In terms of profitability, INCY's ROE is +0.30%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, INCY is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for INCY.Check CNTA's competition here
Xenon Pharmaceuticals Inc. (NASDAQ: XENE)
INCY vs XENE Comparison August 2026
Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCY stands at 24.2B. In comparison, XENE has a market cap of 6.1B. Regarding current trading prices, INCY is priced at $119.52 on the NASDAQ, while XENE trades at $62.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCY currently has a P/E ratio of 16.06, whereas XENE's P/E ratio is -13.33. In terms of profitability, INCY's ROE is +0.30%, compared to XENE's ROE of -0.49%. Regarding short-term risk, INCY is more volatile compared to XENE. This indicates higher risk in terms of short-term price fluctuations for INCY.Check XENE's competition here
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
INCY vs LGND Comparison August 2026
Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCY stands at 24.2B. In comparison, LGND has a market cap of 5.8B. Regarding current trading prices, INCY is priced at $119.52 on the NASDAQ, while LGND trades at $287.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCY currently has a P/E ratio of 16.06, whereas LGND's P/E ratio is 34.48. In terms of profitability, INCY's ROE is +0.30%, compared to LGND's ROE of +0.16%. Regarding short-term risk, INCY is less volatile compared to LGND. This indicates lower risk in terms of short-term price fluctuations for INCY.Check LGND's competition here
Scholar Rock Holding Corporation (NASDAQ: SRRK)
INCY vs SRRK Comparison August 2026
Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCY stands at 24.2B. In comparison, SRRK has a market cap of 5.7B. Regarding current trading prices, INCY is priced at $119.52 on the NASDAQ, while SRRK trades at $47.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCY currently has a P/E ratio of 16.06, whereas SRRK's P/E ratio is -13.17. In terms of profitability, INCY's ROE is +0.30%, compared to SRRK's ROE of -1.64%. Regarding short-term risk, INCY is less volatile compared to SRRK. This indicates lower risk in terms of short-term price fluctuations for INCY.Check SRRK's competition here
PTC Therapeutics, Inc. (NASDAQ: PTCT)
INCY vs PTCT Comparison August 2026
Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCY stands at 24.2B. In comparison, PTCT has a market cap of 5.6B. Regarding current trading prices, INCY is priced at $119.52 on the NASDAQ, while PTCT trades at $68.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCY currently has a P/E ratio of 16.06, whereas PTCT's P/E ratio is -29.19. In terms of profitability, INCY's ROE is +0.30%, compared to PTCT's ROE of +0.22%. Regarding short-term risk, INCY is less volatile compared to PTCT. This indicates lower risk in terms of short-term price fluctuations for INCY.Check PTCT's competition here
Cidara Therapeutics, Inc. (NASDAQ: CDTX)
INCY vs CDTX Comparison August 2026
Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCY stands at 24.2B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, INCY is priced at $119.52 on the NASDAQ, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCY currently has a P/E ratio of 16.06, whereas CDTX's P/E ratio is -19.77. In terms of profitability, INCY's ROE is +0.30%, compared to CDTX's ROE of -0.37%. Regarding short-term risk, INCY is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for INCY.Check CDTX's competition here
Abcam plc (NASDAQ: ABCM)
INCY vs ABCM Comparison August 2026
Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCY stands at 24.2B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, INCY is priced at $119.52 on the NASDAQ, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCY currently has a P/E ratio of 16.06, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, INCY's ROE is +0.30%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, INCY is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for INCY.Check ABCM's competition here
IVERIC bio, Inc. (NASDAQ: ISEE)
INCY vs ISEE Comparison August 2026
Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCY stands at 24.2B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, INCY is priced at $119.52 on the NASDAQ, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCY currently has a P/E ratio of 16.06, whereas ISEE's P/E ratio is -22.44. In terms of profitability, INCY's ROE is +0.30%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, INCY is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for INCY.Check ISEE's competition here
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)
INCY vs APLS Comparison August 2026
Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCY stands at 24.2B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, INCY is priced at $119.52 on the NASDAQ, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCY currently has a P/E ratio of 16.06, whereas APLS's P/E ratio is 38.35. In terms of profitability, INCY's ROE is +0.30%, compared to APLS's ROE of +0.40%. Regarding short-term risk, INCY is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for INCY.Check APLS's competition here
Travere Therapeutics, Inc. (NASDAQ: TVTX)
INCY vs TVTX Comparison August 2026
Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCY stands at 24.2B. In comparison, TVTX has a market cap of 5.2B. Regarding current trading prices, INCY is priced at $119.52 on the NASDAQ, while TVTX trades at $55.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCY currently has a P/E ratio of 16.06, whereas TVTX's P/E ratio is -254.05. In terms of profitability, INCY's ROE is +0.30%, compared to TVTX's ROE of -0.27%. Regarding short-term risk, INCY is less volatile compared to TVTX. This indicates lower risk in terms of short-term price fluctuations for INCY.Check TVTX's competition here
Terns Pharmaceuticals, Inc. (NASDAQ: TERN)
INCY vs TERN Comparison August 2026
Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCY stands at 24.2B. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, INCY is priced at $119.52 on the NASDAQ, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCY currently has a P/E ratio of 16.06, whereas TERN's P/E ratio is -51.41. In terms of profitability, INCY's ROE is +0.30%, compared to TERN's ROE of -0.20%. Regarding short-term risk, INCY is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for INCY.Check TERN's competition here
Definium Therapeutics, Inc. (NASDAQ: DFTX)
INCY vs DFTX Comparison August 2026
Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCY stands at 24.2B. In comparison, DFTX has a market cap of 4.7B. Regarding current trading prices, INCY is priced at $119.52 on the NASDAQ, while DFTX trades at $43.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCY currently has a P/E ratio of 16.06, whereas DFTX's P/E ratio is N/A. In terms of profitability, INCY's ROE is +0.30%, compared to DFTX's ROE of -1.02%. Regarding short-term risk, INCY is less volatile compared to DFTX. This indicates lower risk in terms of short-term price fluctuations for INCY.Check DFTX's competition here
Dyne Therapeutics, Inc. (NASDAQ: DYN)
INCY vs DYN Comparison August 2026
Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCY stands at 24.2B. In comparison, DYN has a market cap of 4.6B. Regarding current trading prices, INCY is priced at $119.52 on the NASDAQ, while DYN trades at $25.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCY currently has a P/E ratio of 16.06, whereas DYN's P/E ratio is -7.82. In terms of profitability, INCY's ROE is +0.30%, compared to DYN's ROE of -0.64%. Regarding short-term risk, INCY is less volatile compared to DYN. This indicates lower risk in terms of short-term price fluctuations for INCY.Check DYN's competition here
CRISPR Therapeutics AG (NASDAQ: CRSP)
INCY vs CRSP Comparison August 2026
Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCY stands at 24.2B. In comparison, CRSP has a market cap of 4.6B. Regarding current trading prices, INCY is priced at $119.52 on the NASDAQ, while CRSP trades at $47.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCY currently has a P/E ratio of 16.06, whereas CRSP's P/E ratio is -9.39. In terms of profitability, INCY's ROE is +0.30%, compared to CRSP's ROE of -0.31%. Regarding short-term risk, INCY is similarly volatile compared to CRSP. This indicates similar risk in terms of short-term price fluctuations for INCY.Check CRSP's competition here
Amicus Therapeutics, Inc. (NASDAQ: FOLD)
INCY vs FOLD Comparison August 2026
Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCY stands at 24.2B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, INCY is priced at $119.52 on the NASDAQ, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCY currently has a P/E ratio of 16.06, whereas FOLD's P/E ratio is -161.00. In terms of profitability, INCY's ROE is +0.30%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, INCY is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for INCY.Check FOLD's competition here
Akero Therapeutics, Inc. (NASDAQ: AKRO)
INCY vs AKRO Comparison August 2026
Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCY stands at 24.2B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, INCY is priced at $119.52 on the NASDAQ, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCY currently has a P/E ratio of 16.06, whereas AKRO's P/E ratio is -14.57. In terms of profitability, INCY's ROE is +0.30%, compared to AKRO's ROE of -0.22%. Regarding short-term risk, INCY is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for INCY.Check AKRO's competition here
Dianthus Therapeutics, Inc. (NASDAQ: DNTH)
INCY vs DNTH Comparison August 2026
Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCY stands at 24.2B. In comparison, DNTH has a market cap of 4.5B. Regarding current trading prices, INCY is priced at $119.52 on the NASDAQ, while DNTH trades at $106.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCY currently has a P/E ratio of 16.06, whereas DNTH's P/E ratio is -25.89. In terms of profitability, INCY's ROE is +0.30%, compared to DNTH's ROE of -0.02%. Regarding short-term risk, INCY is less volatile compared to DNTH. This indicates lower risk in terms of short-term price fluctuations for INCY.Check DNTH's competition here
Alpine Immune Sciences, Inc. (NASDAQ: ALPN)
INCY vs ALPN Comparison August 2026
Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCY stands at 24.2B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, INCY is priced at $119.52 on the NASDAQ, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCY currently has a P/E ratio of 16.06, whereas ALPN's P/E ratio is -101.52. In terms of profitability, INCY's ROE is +0.30%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, INCY is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for INCY.Check ALPN's competition here
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD)
INCY vs ACAD Comparison August 2026
Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCY stands at 24.2B. In comparison, ACAD has a market cap of 4.4B. Regarding current trading prices, INCY is priced at $119.52 on the NASDAQ, while ACAD trades at $25.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCY currently has a P/E ratio of 16.06, whereas ACAD's P/E ratio is 12.68. In terms of profitability, INCY's ROE is +0.30%, compared to ACAD's ROE of +0.36%. Regarding short-term risk, INCY is less volatile compared to ACAD. This indicates lower risk in terms of short-term price fluctuations for INCY.Check ACAD's competition here
Caris Life Sciences, Inc. (NASDAQ: CAI)
INCY vs CAI Comparison August 2026
Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCY stands at 24.2B. In comparison, CAI has a market cap of 4.4B. Regarding current trading prices, INCY is priced at $119.52 on the NASDAQ, while CAI trades at $15.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCY currently has a P/E ratio of 16.06, whereas CAI's P/E ratio is -86.19. In terms of profitability, INCY's ROE is +0.30%, compared to CAI's ROE of +0.06%. Regarding short-term risk, INCY is less volatile compared to CAI. This indicates lower risk in terms of short-term price fluctuations for INCY.Check CAI's competition here
Veradermics, Incorporated (NYSE: MANE)
INCY vs MANE Comparison August 2026
Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCY stands at 24.2B. In comparison, MANE has a market cap of 4.4B. Regarding current trading prices, INCY is priced at $119.52 on the NASDAQ, while MANE trades at $105.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCY currently has a P/E ratio of 16.06, whereas MANE's P/E ratio is -33.36. In terms of profitability, INCY's ROE is +0.30%, compared to MANE's ROE of -0.84%. Regarding short-term risk, INCY is less volatile compared to MANE. This indicates lower risk in terms of short-term price fluctuations for INCY.Check MANE's competition here
Opthea Limited (NASDAQ: OPT)
INCY vs OPT Comparison August 2026
Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCY stands at 24.2B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, INCY is priced at $119.52 on the NASDAQ, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCY currently has a P/E ratio of 16.06, whereas OPT's P/E ratio is -1.52. In terms of profitability, INCY's ROE is +0.30%, compared to OPT's ROE of +1.18%. Regarding short-term risk, INCY is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for INCY.Check OPT's competition here
PureTech Health plc (NASDAQ: PRTC)
INCY vs PRTC Comparison August 2026
Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCY stands at 24.2B. In comparison, PRTC has a market cap of 4.2B. Regarding current trading prices, INCY is priced at $119.52 on the NASDAQ, while PRTC trades at $17.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCY currently has a P/E ratio of 16.06, whereas PRTC's P/E ratio is -3.78. In terms of profitability, INCY's ROE is +0.30%, compared to PRTC's ROE of -0.32%. Regarding short-term risk, INCY is more volatile compared to PRTC. This indicates higher risk in terms of short-term price fluctuations for INCY.Check PRTC's competition here
Celcuity Inc. (NASDAQ: CELC)
INCY vs CELC Comparison August 2026
Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCY stands at 24.2B. In comparison, CELC has a market cap of 4.2B. Regarding current trading prices, INCY is priced at $119.52 on the NASDAQ, while CELC trades at $86.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCY currently has a P/E ratio of 16.06, whereas CELC's P/E ratio is -22.15. In terms of profitability, INCY's ROE is +0.30%, compared to CELC's ROE of -2.45%. Regarding short-term risk, INCY is more volatile compared to CELC. This indicates higher risk in terms of short-term price fluctuations for INCY.Check CELC's competition here
Edgewise Therapeutics, Inc. (NASDAQ: EWTX)
INCY vs EWTX Comparison August 2026
Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCY stands at 24.2B. In comparison, EWTX has a market cap of 4.1B. Regarding current trading prices, INCY is priced at $119.52 on the NASDAQ, while EWTX trades at $38.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCY currently has a P/E ratio of 16.06, whereas EWTX's P/E ratio is -23.15. In terms of profitability, INCY's ROE is +0.30%, compared to EWTX's ROE of -0.33%. Regarding short-term risk, INCY is less volatile compared to EWTX. This indicates lower risk in terms of short-term price fluctuations for INCY.Check EWTX's competition here
Mirati Therapeutics, Inc. (NASDAQ: MRTX)
INCY vs MRTX Comparison August 2026
Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCY stands at 24.2B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, INCY is priced at $119.52 on the NASDAQ, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCY currently has a P/E ratio of 16.06, whereas MRTX's P/E ratio is -4.82. In terms of profitability, INCY's ROE is +0.30%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, INCY is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for INCY.Check MRTX's competition here
Enliven Therapeutics, Inc. (NASDAQ: ELVN)
INCY vs ELVN Comparison August 2026
Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCY stands at 24.2B. In comparison, ELVN has a market cap of 3.9B. Regarding current trading prices, INCY is priced at $119.52 on the NASDAQ, while ELVN trades at $54.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCY currently has a P/E ratio of 16.06, whereas ELVN's P/E ratio is -32.82. In terms of profitability, INCY's ROE is +0.30%, compared to ELVN's ROE of -0.21%. Regarding short-term risk, INCY is less volatile compared to ELVN. This indicates lower risk in terms of short-term price fluctuations for INCY.Check ELVN's competition here
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX)
INCY vs CPRX Comparison August 2026
Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCY stands at 24.2B. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, INCY is priced at $119.52 on the NASDAQ, while CPRX trades at $31.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCY currently has a P/E ratio of 16.06, whereas CPRX's P/E ratio is 12.30. In terms of profitability, INCY's ROE is +0.30%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, INCY is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for INCY.Check CPRX's competition here
RayzeBio, Inc. Common Stock (NASDAQ: RYZB)
INCY vs RYZB Comparison August 2026
Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCY stands at 24.2B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, INCY is priced at $119.52 on the NASDAQ, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCY currently has a P/E ratio of 16.06, whereas RYZB's P/E ratio is -57.86. In terms of profitability, INCY's ROE is +0.30%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, INCY is more volatile compared to RYZB. This indicates higher risk in terms of short-term price fluctuations for INCY.Check RYZB's competition here
CymaBay Therapeutics, Inc. (NASDAQ: CBAY)
INCY vs CBAY Comparison August 2026
Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCY stands at 24.2B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, INCY is priced at $119.52 on the NASDAQ, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCY currently has a P/E ratio of 16.06, whereas CBAY's P/E ratio is -32.81. In terms of profitability, INCY's ROE is +0.30%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, INCY is more volatile compared to CBAY. This indicates higher risk in terms of short-term price fluctuations for INCY.Check CBAY's competition here
Viking Therapeutics, Inc. (NASDAQ: VKTX)
INCY vs VKTX Comparison August 2026
Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCY stands at 24.2B. In comparison, VKTX has a market cap of 3.7B. Regarding current trading prices, INCY is priced at $119.52 on the NASDAQ, while VKTX trades at $31.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCY currently has a P/E ratio of 16.06, whereas VKTX's P/E ratio is -7.67. In terms of profitability, INCY's ROE is +0.30%, compared to VKTX's ROE of -0.95%. Regarding short-term risk, INCY is less volatile compared to VKTX. This indicates lower risk in terms of short-term price fluctuations for INCY.Check VKTX's competition here
Denali Therapeutics Inc. (NASDAQ: DNLI)
INCY vs DNLI Comparison August 2026
Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCY stands at 24.2B. In comparison, DNLI has a market cap of 3.7B. Regarding current trading prices, INCY is priced at $119.52 on the NASDAQ, while DNLI trades at $23.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCY currently has a P/E ratio of 16.06, whereas DNLI's P/E ratio is -7.99. In terms of profitability, INCY's ROE is +0.30%, compared to DNLI's ROE of -0.52%. Regarding short-term risk, INCY is less volatile compared to DNLI. This indicates lower risk in terms of short-term price fluctuations for INCY.Check DNLI's competition here
Oruka Therapeutics, Inc. (NASDAQ: ORKA)
INCY vs ORKA Comparison August 2026
Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCY stands at 24.2B. In comparison, ORKA has a market cap of 3.6B. Regarding current trading prices, INCY is priced at $119.52 on the NASDAQ, while ORKA trades at $96.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCY currently has a P/E ratio of 16.06, whereas ORKA's P/E ratio is -49.75. In terms of profitability, INCY's ROE is +0.30%, compared to ORKA's ROE of -0.26%. Regarding short-term risk, INCY is less volatile compared to ORKA. This indicates lower risk in terms of short-term price fluctuations for INCY.Check ORKA's competition here
Adaptive Biotechnologies Corporation (NASDAQ: ADPT)
INCY vs ADPT Comparison August 2026
Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCY stands at 24.2B. In comparison, ADPT has a market cap of 3.6B. Regarding current trading prices, INCY is priced at $119.52 on the NASDAQ, while ADPT trades at $22.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCY currently has a P/E ratio of 16.06, whereas ADPT's P/E ratio is -41.80. In terms of profitability, INCY's ROE is +0.30%, compared to ADPT's ROE of -0.31%. Regarding short-term risk, INCY is less volatile compared to ADPT. This indicates lower risk in terms of short-term price fluctuations for INCY.Check ADPT's competition here
Alumis Inc. (NASDAQ: ALMS)
INCY vs ALMS Comparison August 2026
Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCY stands at 24.2B. In comparison, ALMS has a market cap of 3.6B. Regarding current trading prices, INCY is priced at $119.52 on the NASDAQ, while ALMS trades at $28.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCY currently has a P/E ratio of 16.06, whereas ALMS's P/E ratio is -7.39. In terms of profitability, INCY's ROE is +0.30%, compared to ALMS's ROE of -0.55%. Regarding short-term risk, INCY is less volatile compared to ALMS. This indicates lower risk in terms of short-term price fluctuations for INCY.Check ALMS's competition here
Arcus Biosciences, Inc. (NYSE: RCUS)
INCY vs RCUS Comparison August 2026
Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCY stands at 24.2B. In comparison, RCUS has a market cap of 3.5B. Regarding current trading prices, INCY is priced at $119.52 on the NASDAQ, while RCUS trades at $28.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCY currently has a P/E ratio of 16.06, whereas RCUS's P/E ratio is -8.66. In terms of profitability, INCY's ROE is +0.30%, compared to RCUS's ROE of -0.69%. Regarding short-term risk, INCY is less volatile compared to RCUS. This indicates lower risk in terms of short-term price fluctuations for INCY.Check RCUS's competition here
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX)
INCY vs SWTX Comparison August 2026
Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCY stands at 24.2B. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, INCY is priced at $119.52 on the NASDAQ, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCY currently has a P/E ratio of 16.06, whereas SWTX's P/E ratio is -13.78. In terms of profitability, INCY's ROE is +0.30%, compared to SWTX's ROE of -0.47%. Regarding short-term risk, INCY is more volatile compared to SWTX. This indicates higher risk in terms of short-term price fluctuations for INCY.Check SWTX's competition here
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT)
INCY vs ARQT Comparison August 2026
Incyte Corporation (NASDAQ: INCY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INCY stands at 24.2B. In comparison, ARQT has a market cap of 3.5B. Regarding current trading prices, INCY is priced at $119.52 on the NASDAQ, while ARQT trades at $26.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INCY currently has a P/E ratio of 16.06, whereas ARQT's P/E ratio is -933.00. In terms of profitability, INCY's ROE is +0.30%, compared to ARQT's ROE of -0.01%. Regarding short-term risk, INCY is less volatile compared to ARQT. This indicates lower risk in terms of short-term price fluctuations for INCY.Check ARQT's competition here